CD7 Expression Tied to Poorer Outcomes With Newly Diagnosed Leukemia
By Lori Solomon HealthDay Reporter
FRIDAY, May 3, 2024 -- CD7 expression is associated with poorer outcomes in patients with newly diagnosed acute myeloid leukemia (AML), according to a study published online April 11 in the British Journal of Haematology.
Wei-Ying Jen, B.M., B.Ch., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues collected flow cytometry data on 901 patients with AML and examined aberrant CD7 expression on leukemic blasts.
The researchers found that 29.2 percent had blasts positive for CD7. Adverse risk was more likely (64.6 versus 55.6 percent) and favorable risk was less likely (15.2 versus 24.1 percent) with CD7-positive AML by European LeukemiaNet 2022 criteria. Additionally, overall survival was inferior (11.9 versus 19.0 months). Moderate instability over time was seen, with 30.4 percent losing and 19.0 percent gaining CD7 at relapse.
"In summary, we report on a large population of AML with attention to CD7 expression, genomic profiles and patient outcomes," the authors write. "The retrospective nature of the study and the number of associated cytomolecular characteristics require a large sample size, and the identification of any associations will require further evaluation and confirmation in independent datasets."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
Oldest Adults With Acute Myeloid Leukemia Benefit From Venetoclax
THURSDAY, May 16, 2024 -- For older adults with acute myeloid leukemia (AML), venetoclax (VEN) combined with a hypomethylating agent (HMA) is safe and effective and can prolong...
Improvements Seen in Post-Allo-HCT Outcomes for Seniors With Leukemia
THURSDAY, March 28, 2024 -- For older patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (allo-HCT), posttransplant outcomes have...
Worse Overall Survival Seen for Adults With Leukemia With CNS Involvement
WEDNESDAY, Feb. 21, 2024 -- For adults with acute myeloid leukemia (AML), those with central nervous system (CNS) involvement have worse overall survival, according to a review...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.